Cephalon, Inc. Is the exclusive licensee of the '604 and '590 patents. Cephalon is the holder of an approved NDA for the manufacture and sale of fentanyl buccal tablets for the treatment of breakthrough cancer pain.
Cephalon, Inc. Is the exclusive licensee of the '604 and '590 patents. Cephalon is the holder of an approved NDA for the manufacture and sale of fentanyl buccal tablets for the treatment of breakthrough cancer pain.
Cephalon, Inc. Is the exclusive licensee of the '604 and '590 patents. Cephalon is the holder of an approved NDA for the manufacture and sale of fentanyl buccal tablets for the treatment of breakthrough cancer pain.